Skip to main content

Table 3 Review of literatures reporting bevacizumab treatment for meningiomas

From: Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas

Authors Tumor Prior Tx Bevacizumab Treatment duration Radiological assessment Response PFS/OS Toxicity
Putchner MJA, et al. 2010 [4] 1 Anaplstic 60Gy RT 10 mg/kg every 2 weeks 6 months N/A 1 PR N/A hypertension
Goutagny S, et al. 2011 [17] 7 tumors in NF2 pts none 5 mg/kg Every 2 weeks 15 months volume 1 tumor: 22 % decrease N/A No mention
6 tumors N/C
Lou E, et al. 2012 [5] 5 GI RT: 12/14 10 mg/kg very 2 weeks 0.5–29.5 months RANO 0 CR mPFS: 17.9 months Tumoral hemorrhage
5 GII CT: 11/14     1 PR PFS-6: 85.7 % G4 intestinal perforation
3 GIII      11 SD   G5 pneumonia/sepsis
1 unk      2 PD   
Nayak L, et al. 2012 [18] 6 GII RT: 15/15 10 mg/kg every 2 weeks 9 doses (1–19 doses) RANO 0 CR mPFS: 26 weeks G1 Intratumoral hemorrhage
9 GIII CT: 7/15     0 PR mOS: 15 months G2 fatigue
      15 SD   
Nunes FP, et al. 2013 [19] 48 tumors in 15 NF2 pts   5 mg/kg every 2 weeks   Response: 20 % reduction Tumor: 29 % response Per-tumor 4 G3 events
Progression: 20 % increase Patients PFS-6: 85 % 2 G4 events (wound healing problems)
  7 % response Per-patient  
   PFS-6: 93 %  
Boström JP, et al. 2014 [20] 1 GIII 60Gy RT 5 mg/kg every 2 weeks 2 months N/A Stable and growing N/A No mention
  35Gy SRT